MA33528B1 - Derives pyridin-4-yliques - Google Patents

Derives pyridin-4-yliques

Info

Publication number
MA33528B1
MA33528B1 MA34631A MA34631A MA33528B1 MA 33528 B1 MA33528 B1 MA 33528B1 MA 34631 A MA34631 A MA 34631A MA 34631 A MA34631 A MA 34631A MA 33528 B1 MA33528 B1 MA 33528B1
Authority
MA
Morocco
Prior art keywords
derivatives
bredin
compounds
formula
preparation
Prior art date
Application number
MA34631A
Other languages
Arabic (ar)
English (en)
Inventor
Martin Bolli
Cyrille Lescop
Boris Mathys
Keith Morrison
Claus Mueller
Oliver Nayler
Beat Steiner
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42734812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33528(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA33528B1 publication Critical patent/MA33528B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention porte sur des dérivés de pyridine de formule (i), dans laquelle a, r1, r2, r3 et r4 sont tels que décrits dans la description, sur leur préparation et sur leur utilisation comme composés pharmaceutiquement actifs. Lesdits composés servent en particulier d'agents immunomodulateurs.
MA34631A 2009-07-16 2012-02-14 Derives pyridin-4-yliques MA33528B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009053089 2009-07-16
PCT/IB2010/053224 WO2011007324A1 (fr) 2009-07-16 2010-07-15 Dérivés pyridin-4-yliques

Publications (1)

Publication Number Publication Date
MA33528B1 true MA33528B1 (fr) 2012-08-01

Family

ID=42734812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34631A MA33528B1 (fr) 2009-07-16 2012-02-14 Derives pyridin-4-yliques

Country Status (26)

Country Link
US (1) US8658675B2 (fr)
EP (1) EP2454255B1 (fr)
JP (1) JP5036923B1 (fr)
KR (1) KR101409131B1 (fr)
CN (1) CN102471328B (fr)
AR (1) AR077413A1 (fr)
AU (1) AU2010272219B2 (fr)
BR (1) BR112012000763B8 (fr)
CA (1) CA2767585C (fr)
CY (1) CY1114759T1 (fr)
DK (1) DK2454255T3 (fr)
ES (1) ES2441845T3 (fr)
HR (1) HRP20140098T1 (fr)
IL (1) IL217490A (fr)
MA (1) MA33528B1 (fr)
MX (1) MX2012000414A (fr)
MY (1) MY153617A (fr)
NZ (1) NZ598173A (fr)
PL (1) PL2454255T3 (fr)
PT (1) PT2454255E (fr)
RU (1) RU2547098C2 (fr)
SG (1) SG178042A1 (fr)
SI (1) SI2454255T1 (fr)
TW (1) TWI410421B (fr)
WO (1) WO2011007324A1 (fr)
ZA (1) ZA201201125B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2069336E (pt) 2006-09-07 2013-03-07 Actelion Pharmaceuticals Ltd Derivados de piridin-4-ilo como agentes imunomoduladores
BRPI0808789A2 (pt) 2007-03-16 2014-08-12 Actelion Pharmaceuticals Ltd Compostos e composição farmacêutica de derivados aminopiridina e uso destes
PT2195311E (pt) * 2007-08-17 2011-05-25 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores do receptor s1p1/edg1
KR20100092473A (ko) * 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
EP2262799B1 (fr) * 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Composés de pyridine
CA2715317A1 (fr) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Nouveaux derives d'aminomethylbenzene
WO2009109872A1 (fr) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Dérivés de pyridin-2-yle utilisés comme agents immunomodulateurs
MA34910B1 (fr) * 2011-01-19 2014-02-01 Actelion Pharmaceuticals Ltd Dérivés de 2-methoxy-pyridin-4-yl
EP2852575A1 (fr) * 2012-05-22 2015-04-01 Actelion Pharmaceuticals Ltd. Nouveau procédé de préparation d'acide 2-cyclopentyl-6-méthoxy-isonicotinique
NZ713080A (en) 2013-03-15 2020-06-26 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives
PH12017502097B1 (en) * 2015-05-20 2023-05-05 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
CN110325517B (zh) * 2017-02-28 2021-03-02 南京明德新药研发有限公司 螺环类化合物及其应用
CN107311994A (zh) * 2017-08-14 2017-11-03 淄博职业学院 一种s1p‑1受体激动剂药物分子的新型合成方法
CN107445941A (zh) * 2017-08-14 2017-12-08 河南科技大学第附属医院 具有免疫抑制活性的三氮唑类化合物的制备方法及应用
CN107382965A (zh) * 2017-08-14 2017-11-24 河南科技大学第附属医院 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
CN109369620B (zh) * 2018-12-22 2020-04-14 山东大学 吡啶类化合物及其制备方法与抗胃癌应用
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
WO2021148314A1 (fr) 2020-01-20 2021-07-29 Idorsia Pharmaceuticals Ltd Élimination accélérée de (s)-3-{4-[5-(2-cyclopentyl-6-méthoxy-pyridine-4-yl))- [1,2,4]oxadiazol-3-yl]-2-éthyl-6-méthyl-phénoxy}-propane-1,2-diol
EP4101445B1 (fr) 2020-02-06 2025-04-30 Mitsubishi Tanabe Pharma Corporation Amiselimod pour utilisation dans le traitement de l'encéphalomyélite myalgique/syndrome de fatigue chronique
US11760751B2 (en) 2020-03-04 2023-09-19 Helioeast Science & Technology Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
WO2022213935A1 (fr) * 2021-04-09 2022-10-13 南昌弘益药业有限公司 Composé spirocyclique substitué par oxadiazole et son application
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p
IL319505A (en) 2022-09-14 2025-05-01 Viatris Asia Pacific Pte Ltd S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon
WO2025083549A1 (fr) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Méthodes et combinaisons d'inhibiteurs de la voie il-23 et de modulateurs de la voie de signalisation s1p pour le traitement de maladies auto-immunes

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
AU653957B2 (en) 1990-09-20 1994-10-20 Merrell Dow Pharmaceuticals Inc. 1-aryl-3-pyridinyl-2-propene-1-ones
DE4429465A1 (de) 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
KR100875222B1 (ko) 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
MXPA03007513A (es) 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
RU2331639C2 (ru) * 2002-08-23 2008-08-20 Райджел Фармасьютикалз, Инк. Пиридилзамещенные гетероциклы, пригодные для лечения или профилактики инфекции, вызванной вирусом гепатита с
WO2004035538A1 (fr) 2002-10-15 2004-04-29 Merck & Co., Inc. Procede de fabrication de l'acide azetidine-3-carboxylique
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2005014525A2 (fr) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Compose bi-aryle presentant une activite immunosuppressive
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP1697333A4 (fr) 2003-12-17 2009-07-08 Merck & Co Inc Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
EP1758579A1 (fr) 2004-05-29 2007-03-07 7TM Pharma A/S Ligands des recepteurs crth2 a usages medicaux
WO2006010379A1 (fr) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Nouveaux derives du thiophene utilises comme agents immunosupresseurs
CA2583681A1 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
BRPI0519012A2 (pt) 2004-12-13 2008-12-23 Ono Pharmaceutical Co derivado do Ácido aminocarboxÍlico e seu uso medicinal
KR20080002850A (ko) 2005-03-23 2008-01-04 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
CA2602474C (fr) 2005-03-23 2014-06-10 Actelion Pharmaceuticals Ltd Derives hydrogenes de benzo (c) thiophene utilises comme immunomodulateurs
JP2008534689A (ja) 2005-04-05 2008-08-28 ファーマコペイア， インコーポレイテッド 免疫抑制のためのプリン及びイミダゾピリジン誘導体
WO2006115188A1 (fr) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Compose heterocyclique
US8017631B2 (en) 2005-04-26 2011-09-13 Neurosearch A/S Oxadiazole derivatives and their medical use
WO2006131336A1 (fr) 2005-06-08 2006-12-14 Novartis Ag Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p
WO2006135694A2 (fr) 2005-06-10 2006-12-21 Acadia Pharmaceuticals Inc. Composes modulateurs d'uii et utilisation
US7951794B2 (en) 2005-06-24 2011-05-31 Actelion Pharmaceuticals Ltd. Thiophene derivatives
CN101203220A (zh) 2005-06-28 2008-06-18 阿斯利康(瑞典)有限公司 新用途
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
AU2007209051A1 (en) 2006-01-24 2007-08-02 Actelion Pharmaceuticals Ltd Novel pyridine derivatives
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
KR20080096780A (ko) 2006-02-21 2008-11-03 유니버시티 오브 버지니아 페이턴트 파운데이션 Ｓ１ｐ 수용체 효능제로서의 페닐-시클로알킬 및 페닐-헤테로시클릭 유도체
EP2258700A1 (fr) 2006-05-09 2010-12-08 Pfizer Products Inc. Dérivés d'acides aminés cycloalkyles et compositions pharmaceutiques les contenant
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
PT2069336E (pt) 2006-09-07 2013-03-07 Actelion Pharmaceuticals Ltd Derivados de piridin-4-ilo como agentes imunomoduladores
PL2069335T3 (pl) 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
ES2393412T3 (es) 2006-09-21 2012-12-21 Actelion Pharmaceuticals Ltd. Derivados de fenilo y su uso como inmunomoduladores
CN101522646A (zh) 2006-09-29 2009-09-02 诺瓦提斯公司 具有抗炎和免疫抑制特性的二唑衍生物
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
EP2109364A4 (fr) 2006-12-15 2010-04-14 Abbott Lab Composés d'oxadiazole innovants
WO2008091967A1 (fr) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Composés chimiques
BRPI0808789A2 (pt) * 2007-03-16 2014-08-12 Actelion Pharmaceuticals Ltd Compostos e composição farmacêutica de derivados aminopiridina e uso destes
PT2195311E (pt) 2007-08-17 2011-05-25 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores do receptor s1p1/edg1
CN104478821B (zh) 2007-10-04 2016-09-28 默克雪兰诺有限公司 噁二唑二芳基化合物
MX2010003612A (es) 2007-10-04 2010-04-30 Merck Serono Sa Derivados de oxadiazol.
KR20100092473A (ko) 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
JP2011503046A (ja) 2007-11-08 2011-01-27 ファイザー・インク シクロブチルカルボン酸誘導体
MX2010005889A (es) 2007-12-10 2010-06-22 Actelion Pharmaceuticals Ltd Derivados de tiofeno como agonistas de s1p1/edg1.
WO2009109907A1 (fr) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Nouveaux dérivés de pyrimidine-pyridine
EP2262799B1 (fr) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Composés de pyridine
CA2715317A1 (fr) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Nouveaux derives d'aminomethylbenzene
WO2009109872A1 (fr) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Dérivés de pyridin-2-yle utilisés comme agents immunomodulateurs
EP3782991A1 (fr) 2008-05-14 2021-02-24 The Scripps Research Institute Nouveaux modulateurs de récepteurs de la sphingosine phosphate
EP2445891A4 (fr) 2009-06-26 2012-11-14 Glaxo Group Ltd Dérivés hétéroaryliques à 5 chaînons utilisés comme agonistes de récepteurs à la sphingosine-1-phosphate

Also Published As

Publication number Publication date
CA2767585C (fr) 2017-09-26
KR101409131B1 (ko) 2014-06-17
TW201107313A (en) 2011-03-01
ZA201201125B (en) 2014-07-30
EP2454255A1 (fr) 2012-05-23
IL217490A0 (en) 2012-02-29
JP5036923B1 (ja) 2012-09-26
AU2010272219A1 (en) 2012-03-08
JP2012533533A (ja) 2012-12-27
BR112012000763B8 (pt) 2021-05-25
CY1114759T1 (el) 2016-12-14
BR112012000763A2 (pt) 2018-03-13
DK2454255T3 (da) 2013-12-16
PT2454255E (pt) 2014-01-14
CN102471328B (zh) 2015-04-01
IL217490A (en) 2015-10-29
AR077413A1 (es) 2011-08-24
PL2454255T3 (pl) 2014-04-30
MX2012000414A (es) 2012-02-08
MY153617A (en) 2015-02-27
BR112012000763B1 (pt) 2021-02-09
CN102471328A (zh) 2012-05-23
HK1170479A1 (en) 2013-03-01
US8658675B2 (en) 2014-02-25
ES2441845T3 (es) 2014-02-06
AU2010272219B2 (en) 2015-02-26
EP2454255B1 (fr) 2013-11-06
US20120108638A1 (en) 2012-05-03
SI2454255T1 (sl) 2014-01-31
RU2547098C2 (ru) 2015-04-10
CA2767585A1 (fr) 2011-01-20
SG178042A1 (en) 2012-03-29
KR20120069662A (ko) 2012-06-28
WO2011007324A1 (fr) 2011-01-20
TWI410421B (zh) 2013-10-01
RU2012105134A (ru) 2013-08-27
NZ598173A (en) 2014-01-31
HRP20140098T1 (hr) 2014-03-14

Similar Documents

Publication Publication Date Title
MA33528B1 (fr) Derives pyridin-4-yliques
MA31988B1 (fr) Derives d'aminopyrazole
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA31289B1 (fr) Derives de thiazolidine
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
MA32173B1 (fr) Derives de pyridin-2-yle utilises comme agents immunomodulateurs
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
MA33420B1 (fr) Dérivés fluorés de l'aminotriazole
MA30231B1 (fr) Derives de benzamides et d'heteroarenes
MA31953B1 (fr) Nouveaux derives du thiophene.
MA32170B1 (fr) Nouveaux derives d'aminomethylbenzene
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
MA31703B1 (fr) Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA31290B1 (fr) Derives d'amino-pyridine comme agonistes du recepteur s1p1/edg1
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA32151B1 (fr) Derives de 2-aza-bicyclo[2.2.1]heptane
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
MA31754B1 (fr) Cis-imidazolines chirales
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k